14% Growth, but PAT Leans on ₹30 Cr Insurance Gain—Normalized Earnings Only ₹15.4 Cr
Revenue and EBITDA margin are on track, but reported profit hides a lumpy quarter. Strip the insurance gain and Flavour inventory buildup, and normalized earnings are half the headline.
The profitability gap
₹45.4 Cr
+77.8% YoY
₹30 Cr
one-time
₹15.4 Cr
~2.3% margin
The headline profit popped 78% year-on-year, but the call and the financials reveal the story: ₹30 crore of the ₹45.4 crore PAT is an insurance settlement, not operating earnings. Strip that out, and normalized profit is ₹15.4 crore, or 2.3% of revenue. That's a healthy quarter by absolute terms, but far from the 6.8% margin the headline implies.
Revenue is tracking; earnings are lumpy
The ₹662.4 crore revenue (+14.1% YoY) is real and on track for management's full-year double-digit guidance. EBITDA expanded 80 basis points to 13.4% (from 12.6% prior year), supporting the ₹300+ crore EBITDA target for the year. But the path to that profit is uneven. Flavour, the largest segment, delivered ₹112 crore, but management disclosed ~₹15 crore of that is inventory buildup driven by customer prepone orders during supply disruptions. Normalized Flavour run-rate is ₹95–96 crore per quarter. That means Q1 is not repeatable at headline rates. Global Ingredients was "softer than expected," and India Fragrance flat YoY despite the group's 14% growth—a sign that domestic demand is tougher than prior calls suggested.
Claims vs. reality
Revenue grew 14% YoY to ₹662 Cr
Delivered ₹662.4 Cr, 14.1% YoY growth
Supported
EBITDA margin improved to 13.4% from 12.6%
Delivered ₹89 Cr EBITDA (13.4% margin)
Supported
Flavour ₹112 Cr includes ~₹15 Cr inventory buildup; normalized ₹95–96 Cr
Management candid on timing; sustainable base is 15–17% lower than Q1 headline
Supported
Passed pricing to 95%+ of clients; where reluctant, withheld supply
Pricing discipline evident; but 5% client resistance not quantified; India Fragrance flat YoY suggests volume loss
Partial—margin protected, but top-line impact masked
Double-digit growth + improved margins for full year FY27
On track for revenue; margins improving. However, normalized PAT is 2.3%, not 6.8%. Insurance gain provides buffer of ₹50–60 Cr pending in rest of year
Slightly overstated—guidance is intact, but underlying operating earnings are weaker
What shifted on this call
Three material changes from prior calls: Net debt rose to ₹852 crore (vs. ₹800 crore prior guidance) due to ₹65 crore strategic inventory buildup and capex acceleration. Management reaffirmed deleveraging from Q3 onwards (₹25 crore per quarter), but the higher starting point signals a more expensive path back. India Fragrance is flat YoY, not growing with the group; management cites a "conscious exit from low-margin business," but the softness also hints at domestic market headwinds. Global Ingredients recovery was pushed to H2 from prior calls' implied gradual ramp; supply chain disruptions have extended the timeline. None of these is a cut to full-year guidance, but they are downgrades to the underlying momentum narrative.
How the market is positioned
The stock rallied +13.5% on day 1 post-result and held +14.3% by day 3, suggesting the market believed the 14% revenue growth and 80 bp margin gain. However, the price is now overbought on technicals (RSI 77.2) and sits 28% below its all-time high of ₹231.28, trading at ₹166.54. FII ownership edged up 63 bp to 7.42% (modest add), while DII trimmed 84 bp to 5.18%—a slight loss of domestic confidence. A small bulk trade on Jul 29 by Elixir Wealth (buy/sell at ₹166.61/₹166.30) shows no insider/promoter-linked activity. The fundamental read (solid revenue growth, lumpy earnings, elevated debt) does not yet justify an overbought technical setup.
Risks ranked by holder concern
Earnings quality: ₹30 Cr insurance gain inflates PAT by 66%
HighNormalized PAT is 2.3% margin. ₹50–60 Cr insurance gain pending in rest of year will create lumpiness. Strip one-timers and organic earnings are half the headline.
Macro sensitivity: geopolitical shocks, supply chain volatility
HighManagement explicitly cited "consistent macroeconomic conditions" as key to growth. Repeat-annuity business vulnerable to sudden geopolitical/inflation shocks. Current hedges (6-month RM contracts, inventory buffer) are tactically sound but not immune to major disruptions.
Flavour lumpiness: ₹15 Cr buildup in Q1 unlikely to repeat
MediumNormalized run-rate ₹95–96 Cr is 15% below Q1 headline. If customer demand weakens post-inventory fill, Q2–Q4 Flavour could miss the ₹95 Cr base case, pressuring full-year EBITDA targets.
Global Ingredients: recovery deferred to H2; supply gap persists
MediumSegment was softer than expected in Q1. Supply chain disruptions from China sourcing constraints curb growth. Backward integration underway but no specific revenue recovery milestones disclosed.
India Fragrance flat despite 14% group growth: domestic market headwind
MediumConscious exit from low-margin business is strategic, but the flatness also signals softer underlying domestic demand. International offset (Europe, USA) is early-stage (Germany breakeven YE26, USA ₹12–16 Cr FY27, UK nascent). Domestic drag limits near-term upside.
Debt elevation: ₹852 Cr vs. ₹800 Cr prior guidance; deleveraging path dependent on cash generation
MediumHigher starting point means costlier path to target debt. Deleveraging ₹25 Cr/qtr from Q3 assumes stable cash generation; macro disruption or Flavour shortfall could extend timeline.
Europe ventures: 3–4 years to ramp; breakeven milestones (Germany YE26, USA/UK year later each) are ambitious
MediumCapex ₹140 Cr FY27 and ongoing R&D ₹3–4 crore/year are sunk into long-cycle investments. Any market entry misstep or adoption lag in Germany, USA, or UK delays breakeven and drags group ROCE.
The debate
Bull-bear ledger
Revenue 14% YoY; double-digit full-year on track
EBITDA margin +80 bp to 13.4%; ₹300+ Cr full-year target intact
Pricing power evident: 95%+ customer acceptance on hikes
Capex on plan (₹140 Cr FY27); Vanvate Q3 commissioning expected
Europe ventures have multi-year upside (17–18% target ROCE); $100 M addressable
Reported PAT inflated 66% by ₹30 Cr insurance gain
Normalized PAT ₹15.4 Cr (2.3% margin), not 6.8%
Flavour ₹15 Cr inventory buildup in Q1; normalized ₹95–96 Cr not repeatable
Global Ingredients soft; recovery pushed to H2
India Fragrance flat YoY despite group +14% growth
Net debt ₹852 Cr, up ₹65 Cr; deleveraging from Q3 dependent on cash
Europe ventures 3–4 years to breakeven; execution risk
Stock overbought (RSI 77.2); 28% below ATH but still extended post-pop
What to watch next
1 · Q2 normalized PAT run-rate
Without the ₹30 Cr insurance cushion or a repeat of the ₹15 Cr Flavour inventory buildup, what is the organic operating earnings? If Flavour normalizes to ₹95–96 Cr and other segments hold, normalized PAT should stabilize around ₹15–17 Cr (2.3–2.6% margin). A miss would signal either deeper Flavour weakness or margin compression from pricing resistance.
2 · Flavour segment trajectory Q2 onwards
Management guided ₹95–96 Cr recurring run-rate (normalized from Q1's ₹112 Cr). If Q2 Flavour comes in at or above ₹95 Cr, the normalized base is confirmed. If it dips below ₹90 Cr, customer demand post-inventory fill is weaker than expected, and full-year EBITDA guidance (₹300+ Cr) is at risk.
3 · Debt deleveraging execution from Q3
Management promised ₹25 Cr/qtr reduction starting Q3. This depends on both EBITDA delivery and capital discipline. Insurance settlement (₹50–60 Cr pending in rest of year) would provide a one-time buffer, but operational cash generation is the key. Failure to hit the deleveraging path signals either weakening cash or a strategic shift toward higher debt tolerance.
The verdict
S H Kelkar is executing on a legitimate multi-year strategy: double-digit revenue growth, EBITDA margin expansion, and long-cycle international ventures (Europe, USA, UK) aimed at 17–18% target ROCE. The Q1 result supports the revenue narrative and validates the margin path. But the quarter also reveals the complexity: reported PAT is inflated 66% by a one-time insurance gain, Flavour is lumpy with ₹15 crore of inventory pull-forward, and domestic fragrance demand is soft despite pricing discipline. Normalized earnings are half the headline, and the path to the ₹300+ crore EBITDA target depends on Flavour normalization, Global Ingredients recovery, and macro stability. Europe ventures remain 3–4 years from breakeven and are a long-term option, not a near-term driver.
The stock popped +13.5% on the result and is overbought on technicals (RSI 77.2). FII added modestly, DII trimmed—a sign that institutional confidence is cautious. At ₹166.54, down 28% from its all-time high but still extended after the rally, the stock prices in the revenue momentum but does not yet discount the earnings lumpiness and execution risks on debt and ventures. The number to track from here is normalized PAT (ex-insurance, ex-Flavour buildup). If Q2 confirms ₹15–17 Cr run-rate, the growth story is real but slower than the headline suggests. If it misses, the domestic headwind and inventory cycle are deeper than expected.
This is steady execution on a credible long-term plan, not a step-change. Hold if you own it for the revenue growth and EBITDA margin progression; be selective on new entry until the Flavour and Global Ingredients recovery is confirmed in H2, and until debt deleveraging demonstrates operational cash generation.
14% growth masks lumpy earnings; Europe investments ahead of demand
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met FY27 EBITDA guidance trajectory (13.4% on track for ~13.5% H1 guided, ₹300+Cr full-year EBITDA). Revenue on track for double-digit full-year. However, underlying operating quality weaker than headline growth suggests; insurance gain and Flavour timing mask softer baseline.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
14% revenue growth on track and EBITDA margin improved to 13.4%. However, Q1 profitability is inflated by ₹30 Cr insurance gain; normalized PAT only ₹15.4 Cr (~2.3% margin). Flavour segment highly lumpy (₹15 Cr of ₹112 Cr is inventory pull-forward, unlikely to repeat). India Fragrance soft despite pricing discipline. Key risk: macro sensitivity (geopolitical, inflation) and early-stage Europe ventures require 3 years to breakeven.
₹662.4 Cr
Revenue · +14.1% YoY₹45.4 Cr
Reported PAT · +77.8% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 14% YoY to ₹662 Cr
METDelivered ₹662.4 Cr, 14.1% YoY growth
EBITDA margin improved to 13.4% from 12.6% prior year
METDelivered ₹89 Cr EBITDA (13.4% margin), prior Q1 12.6%
Flavour ₹112 Cr includes ~₹15 Cr inventory buildup; normalized ₹95-96 Cr
METManagement qualified Flavour growth as lumpy with timing-driven orders; sustainable base is 15-17% lower
India Fragrance flat YoY due to conscious exit from low-margin business
METDelivered result corroborates; management chose pricing discipline over volume to maintain margins
Passed pricing to 95%+ of clients; where reluctant, withheld supply
PartialManagement acknowledged some client resistance but does not disclose volume loss magnitude
Double-digit revenue growth + improved margins for full year FY27
OVERSTATEDOn track: Q1 delivers 14% growth, 13.4% EBITDA margin. However, excludes ₹30 Cr insurance gain; normalized PAT only ₹15.4 Cr (~2.3% margin vs 6.8% reported)
Earnings quality
What changed since the last call
Debt trajectory revised slightly higher
Neutral₹852 Cr vs ₹800 Cr prior guidance. Strategic inventory buildup (₹65 Cr added) + capex continued. Deleveraging path reaffirmed (₹25 Cr/qtr from Q3), so not a cut.
India Fragrance demand weaker
DowngradeFlat YoY (vs group +14% growth). Management exited low-margin business proactively; nonetheless, signals domestic market headwind vs prior calls' implied strength.
Flavour normalized lower than run-rate
Neutral₹112 Cr Q1 headline; ₹95-96 Cr normalized sustainable. Management candid on inventory pull-forward, but Q2+ guidance is not formally lowered.
Global Ingredients recovery delayed
Downgrade"Softer quarter" vs prior calls' gradual recovery narrative. Now expects H2 turnaround; supply gap continues Q1-Q2.
Europe venture timeline reaffirmed
MaintainedGermany breakeven by YE26/early FY27; USA & UK a year later each. No acceleration or slip signaled vs prior calls.
The Q&A
Analyst pushback was moderate; focused on profitability guidance range (Abhijit Akella asked for 10-12%+ margin guidance; Kedar declined to quantify beyond 2-3 months), Flavour sustainability (conceded ₹15 Cr lumpiness), and debt elevation (acknowledged but justified by investment phase). Management held firm on macro caution and refusal to over-promise. Did not dodge but resisted precise commitments.
Flavour growth outlook — Abhijit Akella, Kotak Institutional Equities
AnsweredQ1 was ₹112 Cr. Normal basis ~₹95 Cr. ~₹15 Cr is inventory buildup/order preponement. Q2+ normalizes.
FX contribution — Abhijit Akella, Kotak Institutional Equities
Answered9% is like-for-like growth; 5% is FX sales uplift. Rest is pricing/volume.
India Fragrance softness — Abhijit Akella, Kotak Institutional Equities
AnsweredQ1 last year was strong. We consciously exited low-margin business, rationalized sales, disciplined on pricing. Servicing all clients now post-inventory buildup.
EBITDA margin guidance — Abhijit Akella, Kotak Institutional Equities
PartialIf double-digit growth sustained, margins will improve beyond Q1. But can't predict beyond 2-3 months. Cautious on macro.
Gross margins outlook — Abhijit Akella, Kotak Institutional Equities
AnsweredStable YoY, supported by product mix and proactive RM planning. Our 6-month fixed contracts + extra 45-day buffer hedge shocks.
Factory rebuild & expansion timeline — Abhijit Akella, Kotak Institutional Equities
AnsweredVanvate commissioning Q3 FY27. Debt remains ~June level (₹852 Cr), slightly up Sept. Deleveraging from Q3 onwards (₹25 Cr/qtr). ETR 31.5-32%, target <30%.
Long-term market opportunity — Pranav Tendolkar, Rare Enterprises
AnsweredUK/USA market ~20-21% of global fragrance demand vs India 5%. $10B market size; targeting $100M addressable segment over 2-3 years. Skillsets adequate; R&D & patents enable $10B eventual reach over 10 years.
Premium vs mass-market fragrance — Shivam Gupta, Trinetra Asset Managers
AnsweredPremiumization is normal trend with higher disposable income. Muted in high-inflation years. Europe already developed wave-2 products now cross-selling to Asia.
New product contribution — Shivam Gupta, Trinetra Asset Managers
AnsweredAbout 10-11%.
Raw material hedge strategy — Jatin Chawla, RTL Investments
Answered6-month fixed contract visibility + inventory. RM costs fixed for next 6 months from July. Extra 45-day buffer allows recalibration time. No big margin shock expected.
EBITDA margin expansion logic — Jatin Chawla, RTL Investments
PartialCorrect logic. If growth sustains, margins will improve. But can't predict full-year due to macro uncertainty. Guarded stance.
Capex split Europe vs India — Jatin Chawla, RTL Investments
AnsweredQ1: ₹25 Cr in Europe (now completed, operational since May). Q2: ₹25 Cr in Vanvate. Remaining ~₹50 Cr in 3 India plants, decision to defer some to Q1 next year.
European CDC ramp-up & ROIC — Tanish Jhaveri, Boring AMC
AnsweredLong-term ROCE 17-18% in Europe. Full capex cycle done (Germany CDC, Almere factory). 3-4 years to normalize trend line. $3M/yr additional R&D spend. $4-5B new market addressable.
Group-level ROE & ROCE target — Tanish Jhaveri, Boring AMC
AnsweredLong-term target 20% ROCE. Near-term 3-5 years path to 15%. Then ramp-up post breakeven in new ventures.
Gujarat flooding impact — Adwait Javkar, EquiPoise Capital Management
AnsweredNo impact so far.
Depreciation guidance — Ashwin Patil, Intelligent Prosperity Solution
AnsweredCurrently ₹35 Cr/qtr. Post-Vanvate capitalization, expect ₹38-39 Cr/qtr run-rate.
Investment success criteria — Sajal Kapoor, Antifragile Thinking
AnsweredThree new market ventures (Germany, USA, UK) must achieve EBITDA breakeven YoY by year 3. Germany this/next year, USA a year later, UK another year later. This is our milestone.
Key constraint for doubling earnings — Sajal Kapoor, Antifragile Thinking
AnsweredMajor macro disruptions (pandemic-like). Business is repeat annuity; once launched, it sustains. Disruptions affect current + subsequent year pipeline. Stable macro = we can double revenue in 5 years.
Promoter shareholding — Ankur Agarwal, RC Business House Private Limited
Answered~50 lakh shares. ₹30 Cr value of borrowing against shares.
Debt reduction plan — Ankur Agarwal, RC Business House Private Limited
AnsweredDebt will remain elevated next quarter (similar to June ₹852 Cr), may rise slightly Sept. From Q3, reduce ~₹25 Cr/qtr thereafter.
Pricing actions & customer acceptance — Amit Kumar, Determined Investment
PartialCorrected pricing based on cost inflation from geopolitical effect. 95%+ clients accepted. Where reluctant, withheld supply until negotiations complete. Part of reason India Fragrance sales lower.
Global Ingredients turnaround — Bharat Gupta, Fair Value Capital
AnsweredSupply chain disruptions hit Global Ingredients directly. Backward integration (away from China) in place. Disruptions created supply gap; recovery expected H2 FY27.
Insurance claim settlement — Bharat Gupta, Fair Value Capital
Answered₹50-60 Cr pending. Will chase insurers for fulfillment within FY27.
Unilever relationship ramp-up — Bharat Sheth, Quest Investment Managers Private Limited
PartialContinuous stream of projects with Unilever + others. No large breakthrough additions yet. Global clients facing pricing pressure, new product launches muted (especially India).
Europe & USA/UK traction — Bharat Sheth, Quest Investment Managers Private Limited
AnsweredGermany truly on way with regular traction. USA: expect ₹1.5-2 million (≈₹12-16 Cr annually) FY27. UK: just started this year; expect 12-15 months before material business.
Flavours full-year outlook — Bharat Sheth, Quest Investment Managers Private Limited
AnsweredQ2 may be even stronger than ₹95 Cr. Guesstimate ~₹15 Cr of Q1's ₹112 Cr is extra stock buildup. Normalized ₹95-97 Cr. Q2 better than ₹95-96, Q3 better than Q2, etc. Don't expect ₹112+ repeat in Q2.
Global accounts Flavours — Bharat Sheth, Quest Investment Managers Private Limited
AnsweredStarted with some global nutrition companies; nothing substantial yet. Flavour products are new introductions; 3-4 years to material value.
Flavours segment drivers Q1 — Bharat Sheth, Quest Investment Managers Private Limited
AnsweredAcross the board, business as usual. Global Ingredients lower than expected. Otherwise, no specific segment standout. Normal quarter with Flavours outperforming, Global Ingredients below budget.
Guidance
FY27: double-digit revenue growth (maintained)
HighQ1 delivered 14.1% YoY. Management reaffirmed double-digit for full year despite macro caution. Flavour base normalizing ₹95-96 Cr/qtr post Q1 lumpiness.
EBITDA margin improved from Q1 if double-digit growth sustained (maintained)
MediumQ1 at 13.4% (vs guided 13.5% for H1). Management cautious on full-year prediction beyond 2-3 months. Macro & segment softness (Global Ingredients) create downside risk.
FY27 capex ₹140 Cr on track (maintained)
HighQ1: ₹25 Cr (Europe, now complete). Q2: ₹25 Cr (Vanvate). ~₹50 Cr remaining (3 India plants); some deferrable to Q1 FY28.
Risks the call surfaced
Macro sensitivity
HighGeopolitical developments in West Asia driving energy, freight volatility. Product pipeline & launches defer in disruption periods. Repeat-annuity business vulnerable to sudden shocks.
Flavour lumpiness
Medium₹15 Cr of ₹112 Cr Q1 Flavour revenue is inventory buildup from customers preponing orders due to supply uncertainty. Normalized ₹95-96 Cr. If customer demand weakens post inventory fill, Q2+ miss guidance.
Global Ingredients underperformance
MediumSofter quarter on lower demand in select export markets. Backward integration (away from China) underway but disruptions created supply gap. Recovery expected H2, but timing uncertain.
India Fragrance market headwind
MediumFlat YoY growth (vs group +14%) despite conscious exit from low-margin business. Q1 prior year was strong base, but India fragrance growth lagging globally. Pricing passed to 95%+ clients; remaining 5% withheld supply (implied volume loss).
Leverage elevation
MediumNet debt ₹852 Cr vs ₹800 Cr prior guidance. Strategic inventory (₹65 Cr) + capex acceleration pushed leverage higher. Deleveraging target ₹25 Cr/qtr from Q3; but macro disruption could delay cash generation.
Europe venture ramp-up uncertainty
MediumGermany, USA, UK development centers in early ramp-up (invested heavily 2+ years). Germany targeting breakeven by YE26/early FY27. USA minimum ₹12-16 Cr FY27; UK nascent (12-15 months to material business). If adoption slower than expected, ventures will drag group ROCE for 3-4 years.
Management
Score 7/10. Clear, detailed disclosures on Flavour lumpiness (₹15 Cr inventory buildup), pricing actions (95%+ acceptance), and capex splits (Europe ₹25 Cr done, Vanvate ₹25 Cr Q2). Hedged on full-year macro uncertainty; declined to quantify margin range despite analyst ask. Transparent on challenges (Global Ingredients softer, India Fragrance flat, pricing resistance). On track for FY27 revenue (14% Q1, double-digit full-year guided), EBITDA margin (13.4% at 13.5% H1 guided), capex (₹140 Cr on plan). Met prior EBITDA margin guidance for H1. Deleveraging plan reaffirmed but debt slightly elevated vs prior guidance. Mixed: delivered numbers on revenue & margin, but profitability lumpy due to insurance gain & Flavour timing.
1 · Q2-Q3 FY27
Vanvate factory commissioning (Q3). Expected EBITDA margin expansion if Flavour normalizes.
2 · Q3 onwards FY27
Debt deleveraging begins (₹25 Cr/qtr). Reduces financial risk, improves return profile.
3 · H2 FY27
Global Ingredients recovery expected. Supply chain normalization + backward integration benefits.
Key risk: macro sensitivity (geopolitical, inflation) and early-stage Europe ventures require 3 years to breakeven.
SH Kelkar Q1FY27: revenue +14% YoY, adjusted PAT +7%; OPM hits 13.5% guidance mark
PAT +77.81% YoY · revenue +14.09% · margins expanding
₹662.42 Cr
+14.09% YoY
₹45.43 Cr
+77.81% YoY
6.85%
+2.5pp YoY
₹3.28
S H Kelkar's consolidated revenue rose 14.1% YoY to ₹662.4 Cr (₹580.5 Cr in Q1 FY26) and 1.9% sequentially from ₹649.6 Cr in Q4 FY26. Reported PAT for the period jumped 77.8% YoY to ₹45.4 Cr (₹25.6 Cr a year ago) and surged from a near-breakeven ₹1.8 Cr in Q4 FY26 — but both the current and year-ago quarters carry a matching exceptional item: an on-account insurance settlement tied to the April 2024 Vashivali plant fire (₹29.95 Cr this quarter vs ₹35.92 Cr consolidated a year ago). Stripping this out (at each period's blended effective tax rate), adjusted PAT growth is only ~7% YoY (≈₹25.8 Cr vs ≈₹24.1 Cr) — the headline PAT surge is substantially a repeat of last year's insurance-driven boost, not genuine profit growth.
Q1 FY-2027 vs prior quarters
Operating margin (EBITDA-proxy, ex-exceptional, ex-other-income, as % of revenue) expanded to ~13.4-13.8% from ~12.6-12.9% a year ago and ~9.2-9.3% last quarter — squarely in line with management's stated target of holding adjusted EBITDA margins around 13.5% through H1 FY27. The gain was led by the Flavours segment, whose revenue jumped 63.3% YoY (and 78.3% QoQ) to ₹112.0 Cr with segment profit more than doubling to ₹34.2 Cr (+161.7% YoY); Fragrances, the larger segment, grew a steadier 7.4% YoY to ₹547.8 Cr with segment profit up 25.5% to ₹57.4 Cr. The cost of materials ratio was flat at ~58.7% of revenue in both periods, so the margin gain came from segment mix and operating leverage rather than input-cost relief. Net profit margin rose to 6.9% from 4.4% YoY and 0.3% QoQ.
The stock went into the print at ₹143.97, up 8.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management is confident in maintaining current adjusted EBITDA margins (around 13.5%) for the first half of FY2027, supported by secured raw material supply and pricing strategies. While FY2026 saw some impact from portfolio optimization and capacity expansion costs, the company anticipates reaching over Rs. 300 crore
— This quarter: met
External disclosures (business update coverage) put net debt at roughly ₹864 Cr as of June 30, 2026, above management's stated target of holding borrowings near ₹800 Cr with a 10% annual reduction goal — worth watching against the ₹140 Cr FY27 capex plan. No analyst consensus estimate for the quarter could be confirmed via search; available coverage was post-result recaps, not pre-result previews, so the print cannot be benchmarked against Street numbers. Standalone (parent-only) results diverge materially from consolidated: ex-exceptional, standalone swung to a pretax loss of ₹9.6 Cr from a ₹2.8 Cr profit a year ago, with the ₹29.95 Cr insurance credit alone lifting reported standalone PBT to ₹20.3 Cr — the consolidated growth is being driven by subsidiaries (chiefly Flavours), not the parent's core fragrance operations. Separately, the Board approved divesting the wholly-owned, non-core subsidiary Keva Ventures Private Limited (with step-down Amikeva Private Limited) to promoter-group entity Keva Aromatics Private Limited for ₹45.85 lakh; both entities' results are now classified as discontinued operations (₹0.58 Cr profit this quarter vs a ₹0.06 Cr loss a year ago), and the company states this is under 0.1% of consolidated turnover with no meaningful impact on group performance. The filing's covering letter addresses only the board outcomes and the divestment; it carries no separate management commentary on operating performance for the quarter.
W1
Whether adjusted EBITDA margin holds near management's ~13.5% target through H2 FY27 without insurance-settlement support (Q1 EBITDA-proxy ~₹88.7 Cr, ~13.4% of revenue)
W2
Net debt trajectory toward management's ~₹800 Cr target (10% annual reduction goal) from the current ~₹864 Cr, alongside the planned ₹140 Cr FY27 capex
W3
Completion of the Keva Ventures Pvt Ltd stake sale (targeted by December 31, 2026) and confirmation it stays immaterial (<0.1% of consolidated turnover) to group numbers